FierceBiotech8d
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and ...
MedCity News8d
Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health
While Novo Nordisk has established a strong position in metabolic disease with the GLP-1 agonist semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for obesity, the pharmaceutical ...
GEN8d
Novo Nordisk, Valo Health Ink Expanded Up-to-$4.6B AI Collaboration
Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...
Yahoo Finance10d
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
rendering these products less effective or ineffective for conditions such as type 2 diabetes, cardiovascular disease, and chronic weight management. Novo Nordisk also noted 44 documented adverse ...